Malaria: targeting parasite and host cell kinomes.

Area of Science:

• Parasitology
• Drug Discovery
• Molecular Biology

Background:

• Malaria remains a significant global health threat, causing high morbidity and mortality, particularly in developing nations.
• Antimalarial drug resistance and limited pharmaceutical investment pose major challenges to developing new treatments.
• Protein kinases (PKs) are a key target family in drug discovery, with extensive resources available for kinase research.

Purpose of the Study:

• To explore taxon-specific kinases in malaria parasites as potential drug targets.
• To review validated PK targets in Plasmodium falciparum and Plasmodium berghei using reverse genetics.
• To consider targeting host cell PKs essential for parasite survival.

Main Methods:

• Review of existing literature on Plasmodium kinases and drug discovery efforts.
• Analysis of phylogenetic divergence between parasite and human kinomes.
• Discussion of reverse genetics approaches for target validation in Plasmodium species.

Main Results:

• Plasmodium parasites possess unique kinases distinct from human PKs, offering opportunities for selective inhibition.
• Several Plasmodium-specific PKs have been validated as potential drug targets through reverse genetics.
• Host cell PKs essential for parasite survival represent an alternative therapeutic strategy.

Conclusions:

• Exploiting the unique properties of Plasmodium kinases is a promising strategy for novel antimalarial drug development.
• Targeting taxon-specific PKs offers a pathway to overcome drug resistance and improve treatment efficacy.
• Inhibition of essential host PKs presents a viable, albeit indirect, approach to combating malaria infections.